RxDoctor Payments Data

Tamara Reynolds

Nurse Practitioner · Abingdon, VANPI 1881327849

Payments from drug & device makers

$759in general payments, 2019–2025

Across 22 payments — averaging $34.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$359
  • Novo Nordisk$160
  • AstraZeneca$58
  • AbbVie$44
  • Lilly USA, LLC$29
  • Corcept Therapeutics$25
  • plus $84 from 5 others

What the payments were for

  • Food & beverage$759100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$759 in reported general payments places this provider in the 80th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$34,434
Medicare patients
129
Services billed
2,717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide26$34,405
EliquisApixaban45$33,004
OzempicSemaglutide27$31,080
JardianceEmpagliflozin15$21,138
TradjentaLinagliptin25$18,282
XareltoRivaroxaban19$16,208
TrulicityDulaglutide14$15,608
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$10,260
FarxigaDapagliflozin Propanediol15$9,484
SymbicortBudesonide/Formoterol Fumarate21$8,245
Duloxetine Hcl83$4,324
VascepaIcosapent Ethyl11$3,667
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$3,551
Albuterol Sulfate HfaAlbuterol Sulfate92$2,022
Insulin Lispro Kwikpen U-100Insulin Lispro12$1,971

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$29$50,01340 claims
Novo NordiskOzempic$160$31,08027 claims
AstraZenecaFarxiga, Symbicort$58$17,72936 claims
Johnson & JohnsonXarelto$18$16,20819 claims
GSKAnoro Ellipta$17$10,26014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Abingdon

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →